215 related articles for article (PubMed ID: 9709932)
1. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Geisler J; Lundgren S; Berntsen H; Greaves JL; Lønning PE
J Clin Endocrinol Metab; 1998 Aug; 83(8):2687-93. PubMed ID: 9709932
[TBL] [Abstract][Full Text] [Related]
2. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Geisler J; Ekse D; Helle H; Duong NK; Lønning PE
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):90-5. PubMed ID: 18242079
[TBL] [Abstract][Full Text] [Related]
3. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients.
Geisler J; Lien EA; Ekse D; Lønning PE
J Steroid Biochem Mol Biol; 1997; 63(1-3):53-8. PubMed ID: 9449206
[TBL] [Abstract][Full Text] [Related]
4. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Lønning PE; Geisler J; Johannessen DC; Ekse D
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
6. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
Pasqualini JR; Chetrite G; Blacker C; Feinstein MC; Delalonde L; Talbi M; Maloche C
J Clin Endocrinol Metab; 1996 Apr; 81(4):1460-4. PubMed ID: 8636351
[TBL] [Abstract][Full Text] [Related]
8. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
Lønning PE; Ekse D
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):409-12. PubMed ID: 8541238
[TBL] [Abstract][Full Text] [Related]
9. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
Lønning PE; Johannessen DC; Lien EA; Ekse D; Fotsis T; Adlercreutz H
J Steroid Biochem Mol Biol; 1995 May; 52(5):491-6. PubMed ID: 7748814
[TBL] [Abstract][Full Text] [Related]
10. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
11. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
13. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Geisler J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):245-53. PubMed ID: 14623518
[TBL] [Abstract][Full Text] [Related]
15. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
16. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
17. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors in the treatment of postmenopausal breast cancer.
Bajetta E; Zilembo N; Bichisao E
Drugs Aging; 1999 Oct; 15(4):271-83. PubMed ID: 10582774
[TBL] [Abstract][Full Text] [Related]
19. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
20. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]